Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* At least 18 years old~* Subjects must be hospitalized and have the following:~  * proven or high suspicion of SARS-CoV-2 infection and,~ * requiring oxygen supplementation defined as:~ * SpO2 ≤ 92% regardless of supplemental oxygen (ie on room air or on oxygen), or~ * SpO2 ≥ 92% on supplemental O2 and in the opinion of the Investigator it is not safe to decrease or remove the supplemental oxygen~ * require supplemental oxygen of no more than 10 L/minute, and~ * radiologic suspected or proven COVID-19 pneumonitis (chest x-ray or CT scan)~* Female subjects must have a negative pregnancy test~* Willing and able to comply with the treatment schedule and study procedures~Exclusion Criteria:~* Participating in another clinical trial of an investigational treatment for COVID-19~* Methemoglobin \> 3%~* Evidence of severe multi organ failure~* Use of assisted ventilation prior to initiation of iNO~* Pregnancy or positive pregnancy test pre-dose~* Open tracheostomy~* Chronic use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine, nitroprusside, isosorbide, or dapsone at screening~* History or clinical evidence of systolic heart failure, left ventricular dysfunction (LVEF \<40%)~* Subjects reporting massive hemoptysis associated with the current illness or with radiologically proven pulmonary embolus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled Nitric Oxide (iNO) (Type: ACTIVE_COMPARATOR): Pulsed inhaled iNO 125 mcg/kg IBW/hour
- Placebo (Type: SHAM_COMPARATOR): Pulsed inhaled N2, 99.999% gas

Based on this trial design, predict the completion outcome and termination type (if applicable).